MARKET

CTSO

CTSO

Cytosorbents Corp
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.120
-0.240
-10.17%
After Hours: 2.120 0 0.00% 17:00 06/24 EDT
OPEN
2.340
PREV CLOSE
2.360
HIGH
2.380
LOW
2.100
VOLUME
4.45M
TURNOVER
0
52 WEEK HIGH
9.80
52 WEEK LOW
1.690
MARKET CAP
92.35M
P/E (TTM)
-3.1370
1D
5D
1M
3M
1Y
5Y
What Is The Ownership Structure Like For Cytosorbents Corporation (NASDAQ:CTSO)?
Every investor in Cytosorbents Corporation ( NASDAQ:CTSO ) should be aware of the most powerful shareholder groups...
Simply Wall St. · 2d ago
3 Stocks Under $3 Insiders Are Aggressively Buying
The Nasdaq Composite dropped by more than 400 points on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and trad...
Benzinga · 06/13 11:45
CTSO, LIDR and UONE among mid-day movers
Gainers: Aero Clean Technologies (AERC) +49%. Houston American Energy (HUSA) +37%. Jan One (JAN) +37%. Oncorus (ONCR) +41%. Cytosorbents  (CTSO) +33%. Mirati Therapeutics (MRTX) +30%. Omega (OMGA) +27%. Codiak BioSciences (CDAK) +27%. Quantum
Seekingalpha · 06/07 17:10
CytoSorbents to Hold 2022 Annual Meeting of Stockholders Virtually
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will host its Annual Meeting virtually on Tuesday, June 7, 2022, at 10:00 a.m. Easter...
PR Newswire · 06/02 11:00
CytoSorbents Partners with Nikkiso to Distribute the PureADJUST Hemoperfusion Blood Pump and Supplies in 14 Countries
Stand-alone Blood Pump Business Model is expected to Enable Expanded Use and Increased Adoption of CytoSorb® PRINCETON, N.J., June 1, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO),
Benzinga · 06/01 11:03
CytoSorbents to Present at Two Upcoming Investor Conferences
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces management will present at two upcoming in–person investor conferences.
PR Newswire · 05/19 11:00
Cytosorbents Corporation (NASDAQ:CTSO): When Will It Breakeven?
With the business potentially at an important milestone, we thought we'd take a closer look at Cytosorbents...
Simply Wall St. · 05/12 15:58
CytoSorbents's Return On Capital Employed Insights
According to data from Benzinga Pro, during Q1, CytoSorbents's (NASDAQ:CTSO) reported sales totaled $8.69 million. Despite a 3.66% increase in earnings, the company posted a loss of $8.97 million.
Benzinga · 05/12 14:13
More
No Data
Learn about the latest financial forecast of CTSO. Analyze the recent business situations of Cytosorbents Corp through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

20.00%Strong Buy
80.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CTSO stock price target is 9.60 with a high estimate of 16.00 and a low estimate of 6.00.
High16.00
Average9.60
Low6.00
Current 2.120
EPS
Actual
Estimate
-0.17-0.13-0.08-0.04
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 133
Institutional Holdings: 20.43M
% Owned: 46.91%
Shares Outstanding: 43.56M
TypeInstitutionsShares
Increased
24
1.31M
New
13
266.61K
Decreased
28
786.39K
Sold Out
17
535.05K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+1.64%
Healthcare Equipment & Supplies
+2.14%
Key Executives
Non-Executive Chairman/Independent Director
Al Kraus
President/Chief Operating Officer
Vincent Capponi
Chief Executive Officer/Director
Phillip Chan
Chief Financial Officer
Kathleen Bloch
Other
Efthymios Deliargyris
Independent Director
Michael Bator
Independent Director
Edward Jones
Independent Director
Jiny Kim
Independent Director
Alan Sobel
No Data
No Data
About CTSO
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is focused on investigating and commercializing blood purification technology to reduce uncontrolled inflammation in patients with focus in preventing or treating multiple organ failure. The Company's flagship product, CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. CytoSorb is used during and after cardiac surgery to remove inflammatory mediators, such as cytokines, activated compliment and free hemoglobin that can lead to post-operative complications, such as acute kidney injury, lung injury, shock, and stroke. Its purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.

Webull offers kinds of Cytosorbents Corp stock information, including NASDAQ:CTSO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTSO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CTSO stock methods without spending real money on the virtual paper trading platform.